Sodium Chloride for injection

DRUG2 trials

Sponsors

Camp4 Therapeutics Corp., National Institute of Allergy and Infectious Diseases (NIAID)

Conditions

HIV-1Urea cycle disorders (UCD)

Phase 1

Safety and Immunogenicity of Stabilized CH505 TF chTrimer Vaccination in Adults Living With HIV-1 on Suppressive Antiretroviral Therapy

SuspendedNCT06680479

National Institute of Allergy and Infectious Diseases (NIAID)HIV-1

Start: 2025-04-01End: 2028-04-14Target: 30Updated: 2026-03-03

A Double-blind, Placebo-controlled, Single and Multiple Ascending Dose Phase 1 Study of CMP-CPS-001 in Healthy Volunteers and Participants with Abnormal Heterozygous Ornithine Transcarbamylase (OTC) Genotype

Not yet recruitingCTIS2025-520882-37-00

Camp4 Therapeutics Corp.Urea cycle disorders (UCD)

Target: 12Updated: 2025-08-09